您的购物车当前为空
Radretumab (亦称 L19SIP) 是一种全人源单克隆抗体(小免疫蛋白 SIP 格式),特异性针对纤连蛋白 (Fibronectin) 的额外结构域 B (ED-B)。ED-B 是血管生成的关键标志物,在多种实体瘤新生血管的细胞外基质中高表达,但在正常组织中表达极低。Radretumab 常标记放射性同位素(如 131I),通过高亲和力结合肿瘤血管,递送电离辐射以精准杀伤肿瘤细胞。在临床研究中,该抗体被用于治疗多种实体瘤及其脑转移病灶。
别名 雷曲妥单抗
Radretumab (亦称 L19SIP) 是一种全人源单克隆抗体(小免疫蛋白 SIP 格式),特异性针对纤连蛋白 (Fibronectin) 的额外结构域 B (ED-B)。ED-B 是血管生成的关键标志物,在多种实体瘤新生血管的细胞外基质中高表达,但在正常组织中表达极低。Radretumab 常标记放射性同位素(如 131I),通过高亲和力结合肿瘤血管,递送电离辐射以精准杀伤肿瘤细胞。在临床研究中,该抗体被用于治疗多种实体瘤及其脑转移病灶。

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 2,790 | 现货 | |
| 5 mg | ¥ 11,100 | 现货 | |
| 25 mg | ¥ 33,200 | 现货 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | Radretumab (also known as L19SIP) is a fully human monoclonal antibody in a small immunoprotein (SIP) format that specifically targets the extra-domain B (ED-B) of fibronectin. ED-B is a crucial marker of angiogenesis, highly expressed in the extracellular matrix of neovasculature within various solid tumors but nearly absent in normal adult tissues. Radretumab is typically labeled with radioisotopes such as 131I to deliver ionizing radiation directly to tumor sites through high-affinity binding to tumor vessels. In clinical trials, it is investigated for treating solid tumors and associated brain metastases. |
| 别名 | 雷曲妥单抗 |
| 反应种属 | Human |
| 应用 | ELISAFCMFunctional assay |
| 抗体种类 | Monoclonal |
| 缓冲液 | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| 内毒素 | <1.0 EU/mg |
| 同型 | Human IgG1 kappa |
| 推荐同型对照 |
| 偶联 | Unconjugated |
| Uniprot ID | |
| 靶点 | Fibronectin |
| CAS No. | 1253180-81-2 |
| 存储 | Store at -20°C Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 |
对于不同动物的给药剂量换算,您也可以参考 更多